Real-time enrollment status for this multiple myeloma refractory clinical trial
Current Status
Recruiting
Checked: August 27, 2026 at 8:45 PM UTC
| NCT Number | NCT07772024 |
| Recruiting Status | Recruiting |
| Condition | Multiple Myeloma Refractory |
| Phase | PHASE3 |
| Target Enrollment | 450 participants |
| Active Locations | 1 sites in the US |
| Sponsor | CellCentric Ltd. |
| Last Updated on CT.gov | August 19, 2026 (1 week ago) |
As of August 27, 2026: Clinical trial NCT07772024 is currently recruiting participants. This phase3 study for multiple myeloma refractory is actively seeking new participants at 1 location across the United States. The study is sponsored by CellCentric Ltd.. This status information is automatically verified from the official ClinicalTrials.gov registry.
Yes, NCT07772024 is actively recruiting participants as of August 27, 2026. You can check eligibility and apply through HelloStudys.
This trial is recruiting at 1 location in the United States. View all available locations on the full study page.
Check your eligibility and express interest by completing the application form on the study page. A research coordinator will follow up to discuss next steps.
The official ClinicalTrials.gov record for NCT07772024 was last updated 1 week ago (August 19, 2026). HelloStudys verifies this status automatically.